NXTC vs. OCUP, HCWB, NBRV, AADI, GANX, EYEN, CASI, VYNE, IMRX, and UNCY
Should you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Ocuphire Pharma (OCUP), HCW Biologics (HCWB), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), Gain Therapeutics (GANX), Eyenovia (EYEN), CASI Pharmaceuticals (CASI), VYNE Therapeutics (VYNE), Immuneering (IMRX), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical preparations" industry.
Ocuphire Pharma (NASDAQ:OCUP) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
Ocuphire Pharma has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, NextCure has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
NextCure received 43 more outperform votes than Ocuphire Pharma when rated by MarketBeat users. However, 68.00% of users gave Ocuphire Pharma an outperform vote while only 63.64% of users gave NextCure an outperform vote.
15.0% of Ocuphire Pharma shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 8.7% of Ocuphire Pharma shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Ocuphire Pharma presently has a consensus price target of $18.75, indicating a potential upside of 996.43%. NextCure has a consensus price target of $6.00, indicating a potential upside of 267.02%. Given NextCure's stronger consensus rating and higher probable upside, research analysts clearly believe Ocuphire Pharma is more favorable than NextCure.
NextCure has a net margin of 0.00% compared to NextCure's net margin of -59.44%. NextCure's return on equity of -24.57% beat Ocuphire Pharma's return on equity.
Ocuphire Pharma has higher revenue and earnings than NextCure. Ocuphire Pharma is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ocuphire Pharma had 17 more articles in the media than NextCure. MarketBeat recorded 18 mentions for Ocuphire Pharma and 1 mentions for NextCure. Ocuphire Pharma's average media sentiment score of 1.87 beat NextCure's score of -0.11 indicating that NextCure is being referred to more favorably in the news media.
Summary
Ocuphire Pharma beats NextCure on 11 of the 18 factors compared between the two stocks.
Get NextCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NextCure Competitors List
Related Companies and Tools
